This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
Here's Why The Cooper Companies (COO) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Interpreting The Cooper Companies (COO) International Revenue Trends
by Zacks Equity Research
Explore how The Cooper Companies' (COO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
COO Q3 Earnings Beat, 2025 Sales Outlook Lowered, Stock Down
by Zacks Equity Research
Cooper Companies beats on Q3 earnings with 15% EPS growth, but revenue weakness and a trimmed 2025 outlook send shares tumbling.
Why The Cooper Companies (COO) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's What Key Metrics Tell Us About The Cooper Companies (COO) Q3 Earnings
by Zacks Equity Research
Although the revenue and EPS for The Cooper Companies (COO) give a sense of how its business performed in the quarter ended July 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The Cooper Companies (COO) Q3 Earnings Beat Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of +2.80% and -0.50%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?
COO vs. MMSI: Which Stock Is the Better Value Option?
by Zacks Equity Research
COO vs. MMSI: Which Stock Is the Better Value Option?
How Much Upside is Left in The Cooper Companies (COO)? Wall Street Analysts Think 26.47%
by Zacks Equity Research
The consensus price target hints at a 26.5% upside potential for The Cooper Companies (COO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Cooper Companies Likely to Beat Q3 Earnings Estimate on Lens Demand
by Zacks Equity Research
COO's Q3 results may top estimates, powered by strong demand for MyDay lenses, Biofinity gains and surgical product resilience despite fertility softness.
The Cooper Companies (COO) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for The Cooper Companies (COO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended July 2025.
The Cooper Companies (COO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
The Cooper Companies (COO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cooper Companies' Innovation Fuels Growth Amid Macro Headwinds
by Zacks Equity Research
COO leans on innovation and diversification to fuel growth, but fertility softness, tariffs and inventory headwinds weigh on near-term outlook.
Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Plus (PSTV) delivered earnings and revenue surprises of +88.89% and -18.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights McKesson, Cardinal Health, West Pharmaceutical Services and The Cooper Companies
by Zacks Equity Research
Despite tariff headwinds and softer elective procedure demand, McKesson, Cardinal Health, West Pharmaceutical Services, and The Cooper Companies are positioned for steady gains in the dental supplies space.
4 Dental Supplies Stocks Likely to Gain Amid Rising Tariff Risks
by Indrajit Bandyopadhyay
Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and COO.
Becton Dickinson (BDX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of +7.60% and +0.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of +0.36% and +1.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Sustained Product Demand Drive BDX Stock Before Q3 Earnings?
by Zacks Equity Research
BD's third-quarter fiscal 2025 results are likely to benefit from product launches across Medical and Interventional segments, which drive strong revenue potential.
All You Need to Know About The Cooper Companies (COO) Rating Upgrade to Buy
by Zacks Equity Research
The Cooper Companies (COO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
COO or SAUHY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
COO vs. SAUHY: Which Stock Is the Better Value Option?
Will GLP-1 Demand Drive MCK's Top Line This Earnings Season?
by Zacks Equity Research
MCK's Q1 results are expected to reflect strong prescription volume growth from GLP-1 demand, but lower margins may weigh on profitability.
Should Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for GSEW
COO Stock Declines Despite Strong Core Growth Amid Fertility Woes
by Zacks Equity Research
The Cooper Companies grows margins and premium products, but fertility softness, inventory cuts, and tariffs weigh on the near-term outlook.
HOLX vs. COO: Which GYN Surgical Stock Is the Better Investment Now?
by Moumi Mondal
As demand for GYN surgical tools climbs, HOLX and COO battle it out. Find out which stock shows stronger growth momentum now.
Why The Cooper Companies (COO) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.